After these descriptions were provided in 2005, the concept of synthetic lethality was born and PARP inhibitors (PARPi) were developed for the purpose of treating BRCA-mutated patients in which non-cancerous cells have one wild-type allele, whereas cancer cells are BRCA deficient and thus specifically sensitive to PARPi. This evidence concerns the gene PARP1 and cancer.